• PA-824: From Prodrug to Respiratory Assay Strategy

  2026-08-25

  PA-824 is a bicyclic nitroimidazole derivative whose activity against tuberculosis reflects both cell-wall disruption and respiratory stress. This article translates recent pretomanid findings into a state-aware assay strategy for studying Mycobacterium tuberculosis, persistence, synergy, and resistance.

• Gastric Cancer Assembloids for Patient-Specific Drug Testing

  2026-08-24

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell subpopulations from the same tumor. The model preserved clinically relevant tumor–stroma interactions and revealed that stromal composition can reshape gene expression and drug sensitivity, supporting more physiologically informed personalized screening.

• Coronavirus Macrodomains and PARP-Mediated Antiviral Defense

  2026-08-24

  The reference study identifies PARP12 and PARP14 as host factors that restrict coronavirus macrodomain-mutant replication while supporting interferon production. By combining pharmacological inhibition, targeted knockdown, cell-based infection models, and mouse experiments, it shows that the viral macrodomain counteracts PARP-dependent antiviral pressure rather than acting as an isolated viral enzyme.

• CP-673451: PDGFR Selectivity in Glioma Research

  2026-08-23

  CP-673451 is a selective PDGFRα/β inhibitor that connects precise target engagement with angiogenesis and glioma models. This article presents a genotype-aware framework for interpreting PDGFR assays, with special attention to ATRX-deficient high-grade glioma research.

• Fluo-4 AM: Calcium Imaging for Bioelectronic Insight

  2026-08-22

  Fluo-4 AM enables real-time intracellular calcium measurement with a practical workflow for cell signaling, pharmacology, and emerging retinal bioelectronics. This article translates artificial-photoreceptor findings into better calcium-assay design without confusing optical device output with cellular Ca2+ responses.

• Nintedanib in ATRX-Deficient Glioma Research

  2026-08-21

  Nintedanib (BIBF 1120) provides a practical way to interrogate coordinated VEGFR, FGFR, and PDGFR signaling in cancer and angiogenesis models. When paired with ATRX-stratified glioma systems, it can help test whether receptor tyrosine kinase dependence predicts response and whether combination treatment merits deeper study.

• Deuterated CYP51 Inhibitors: C52 and Oteseconazole

  2026-08-20

  The 2025 Journal of Medicinal Chemistry study used molecular hybridization of Oteseconazole and A33 to develop deuterated diphenyl azole alcohol CYP51 inhibitors. Compound C52 combined broad in vitro antifungal, antibiofilm, and antimorphogenic activity with 63.4% oral bioavailability and efficacy in murine infection models, providing a useful framework for next-generation Candida drug discovery.

• Radiotherapy, PD-1/TIGIT Blockade, and CD8+ Memory

  2026-08-20

  The reference study shows that radiotherapy combined with PD-1 and TIGIT blockade produces stronger primary and abscopal tumor control than individual treatments in several syngeneic mouse models. Its mechanistic contribution is to connect M1 macrophage activation, CD8+ T-cell reinvigoration, and durable central memory with treatment-induced systemic immunity.

• Nintedanib (BIBF 1120) in Translational Assays

  2026-08-19

  Nintedanib (BIBF 1120) combines VEGFR, FGFR, and PDGFR inhibition in one research tool for angiogenesis, tumor, and fibrosis models. This guide translates ATRX-sensitive glioma findings into practical assay design, dosing, controls, and troubleshooting strategies.

• PDK4-IN-1 Hydrochloride: From Target to Flux

  2026-08-19

  PDK4-IN-1 hydrochloride is a selective pyruvate dehydrogenase kinase 4 inhibitor for studying PDH activation and metabolic state transitions. This article connects allosteric target engagement with assay interpretation, flux-level readouts, and translational decision-making beyond conventional workflow descriptions.

• Nintedanib (BIBF 1120) Research Workflows

  2026-08-18

  Build reproducible angiokinase-inhibition assays with Nintedanib (BIBF 1120), from ATRX-stratified glioma screens to endothelial and xenograft models. The workflow emphasizes exposure control, receptor-pathway readouts, and combination testing with temozolomide rather than relying on viability data alone.

• SGI-1027, DNMT1, and RB1 in Gastric Cancer

  2026-08-18

  A 2024 Discovery Medicine study links SGI-1027-mediated DNMT1 reduction with increased RB1 expression and suppression of gastric cancer cell growth, migration, invasion, and experimental lung metastasis. The work provides a useful DNMT1–RB1 framework for cancer epigenetics research, while its single-cell-line design and lack of direct methylation mapping limit mechanistic and translational conclusions.

• Carbapenemase Transmission in CREC Across Guangdong

  2026-08-17

  Chen et al. mapped carbapenemase gene carriage, mobility, antimicrobial resistance, and clonal relatedness in 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals. The study shows that blaNDM-1 was frequently plasmid-associated and readily transferable, providing a practical framework for investigating both horizontal gene transfer and hospital-linked dissemination.

• Cabazitaxel (XRP6258): Protocol & QC Guide

  2026-08-17

  Cabazitaxel (XRP6258, SKU B2157) is a water-insoluble semi-synthetic taxane derivative for antiproliferative assays and models of taxane resistance, including systems with P-glycoprotein expression. Use DMSO or ethanol for preparation, apply matched vehicle controls, and avoid long-term storage of solutions or direct aqueous preparation.

• Anti-Diabetic Drugs, Weight Loss, and SGLT2

  2026-08-16

  The 2021 Pharmacological Research review systematically compares weight-loss effects across non-insulin glucose-lowering therapies in type 2 diabetes, moving beyond glycemic control to classify drugs by clinically relevant changes in body weight, BMI, and body composition. Its placement of Ertugliflozin and other SGLT2 inhibitors in a moderate weight-loss category provides useful context for diabetes mellitus research, while also highlighting the limits of cross-study comparisons.

551 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page